



Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders

Ryan W. Himes, MD^{1,2}, Eric H. Chiou, MD¹, Karen Queliza, MD^{1,3}, Dror S. Shouval, MD^{4,5}, Raz Somech, MD⁴, Suneet Agarwal, MD, PhD⁶, Kunal Jajoo, MD⁷, David S. Ziegler, MBBS, MD⁸, Christian P. Kratz, MD⁹, James Huang, MD¹⁰, Tiffany L. Lucas, MD¹⁰, Kasiani C. Myers, MD¹¹, Adam S. Nelson, MBBS, FRACP¹¹, Courtney D. DiNardo, MD¹², Blanche P. Alter, MD, MPH¹³, Neelam Giri, MD¹³, Payal P. Khincha, MD¹³, Lisa J. McReynolds, MD, PhD¹³, Carlo Dufour, MD¹⁴, Filomena Pierri, MD¹⁴, Frederick D. Goldman, MD¹⁵, Youmna Sherif, MD¹⁶, Sharon A. Savage, MD¹³, Tamir Miloh, MD^{1,17}, and Alison A. Bertuch, MD, PhD¹⁸

Objective To describe the clinical features, therapeutic interventions, and patient outcomes of gastrointestinal (GI) hemorrhage in individuals with a telomere biology disorder, including dyskeratosis congenita, Hoyeraal-Hreidarsson syndrome, Revesz syndrome, and Coats plus.

Study design Clinical Care Consortium for Telomere Associated Ailments members were invited to contribute data on individuals with telomere biology disorders at their institutions who experienced GI bleeding. Patient demographic, laboratory, imaging, procedural, and treatment information and outcomes were extracted from the medical record.

Results Sixteen patients who experienced GI hemorrhage were identified at 11 centers. Among 14 patients who underwent genetic testing, 8 had mutations in *TINF2*, 4 had mutations in *CTC1* or *STN1*, and 1 patient each had a mutation in *TERC* and *RTEL1*. Ten patients had a history of hematopoietic cell transplantation. The patients with Coats plus and those without Coats plus had similar clinical features and courses. Angiodysplasia of the stomach and/or small bowel was described in 8 of the 12 patients who underwent endoscopy; only 4 had esophageal varices. Various medical interventions were trialed. No single intervention was uniformly associated with cessation of bleeding, although 1 patient had a sustained response to treatment with bevacizumab. Recurrence was common, and the overall long-term outcome for affected patients was poor.

Conclusions GI bleeding in patients with telomere biology disorders is associated with significant morbidity and with vascular ectasias rather than varices. (*J Pediatr* 2021;230:55-61).

See editorial, p 12

Telomere biology disorders are rare genetic syndromes associated with life-threatening bone marrow failure, pulmonary fibrosis, and cancer predisposition. Dyskeratosis congenita, Hoyeraal-Hreidarsson syndrome, Revesz syndrome, and Coats plus are diagnostic categories on the telomere biology disorder spectrum, based on specific clinical features.^{1,2} For example, bilateral exudative retinopathy (ie, Coats disease) is associated with Revesz syndrome and Coats plus. Traditionally, Coats plus also has been differentiated from other telomere biology disorders, in part by recurrent gastrointestinal (GI) hemorrhage owing to vascular ectasias in the stomach, small intestine, and liver.³⁻⁶

Unifying the telomere biology disorders is the presence of very short lengths of the specialized DNA-protein complexes at chromosome ends, the telomeres.^{7,8} Fifteen genes, all of which encode factors that impact telomere biology, are

| | |
|--------|---|
| APC | Argon plasma coagulation |
| CCCTAA | Clinical Care Consortium for Telomere-Associated Ailments |
| GI | Gastrointestinal |
| HCT | Hematopoietic cell transplantation |
| PRBC | Packed red blood cells |
| RFA | Radiofrequency ablation |

From the ¹Department of Pediatric Gastroenterology, Hepatology and Nutrition, Baylor College of Medicine and Texas Children's Hospital, Houston, TX; ²Section of Gastroenterology and Hepatology, Department of Pediatrics, Ochsner Health, New Orleans, LA; ³Gastroenterology, Hepatology and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, NY; ⁴Pediatric Gastroenterology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel; ⁵Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; ⁶Boston Children's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA; ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA; ⁸Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia; ⁹Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; ¹⁰Division of Hematology/Oncology, Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, CA; ¹¹Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; ¹²MD Anderson Cancer Center, Houston, TX; ¹³Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; ¹⁴Hemato-Oncology-Stem Cell Transplant Pole, IRCCS Giannina Gaslini, Genoa, Italy; ¹⁵Department of Pediatrics, University of Alabama-Birmingham, Birmingham, AL; ¹⁶Department of Surgery, Baylor College of Medicine and Texas Children's Hospital, Houston, TX; ¹⁷Miami Transplant Institute, University of Miami, Miami, FL; and ¹⁸Section of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX

B.A., N.G., P.K., L.M., and S.S. are supported by the intramural research program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute. The other authors declare no conflicts of interest.

0022-3476/\$ - see front matter. © 2020 Elsevier Inc. All rights reserved.
<https://doi.org/10.1016/j.jpeds.2020.09.038>

implicated in the telomere biology disorders; *DKC1*, *TINF2*, *TERT*, and *RETL1* are the genes most commonly mutated in those who present in childhood.⁹ Coats plus is unique in that it has been attributed in >90% of cases to mutations in *CTC1* and, less commonly, to mutations in *STN1* or *POT1*.^{5,6,10,11} Similarly, in all but a single case,¹² only mutations in the *TINF2* gene have been reported in individuals diagnosed with Revesz syndrome.^{13,14}

Along with advances in the genetics of telomere biology disorders has come an increasing awareness of GI features not previously appreciated beyond single case reports. Whereas oral leukoplakia and esophageal webs or strictures, cirrhosis, and GI cancers have been long associated across the telomere biology disorder spectrum,¹⁵⁻¹⁷ additional GI manifestations have been more recently described in case series. Life-threatening enterocolitis or enteropathy in association with B cell deficiency may be the presenting feature, particularly in early childhood.¹⁸ Hepatopulmonary syndrome with noncirrhotic portal hypertension also has been described in children and adults and may be the ultimate cause of death.¹⁹

GI bleeding is being increasingly appreciated by providers in the Clinical Care Consortium of Telomere-Associated Ailments (CCCTAA) as a cause of significant morbidity in patients with telomere biology disorder beyond those with Coats plus. The CCCTAA is an international consortium that aims to improve research and clinical care for individuals with telomere biology disorders. The present study was prompted by discussions at a 2017 workshop sponsored by the CCCTAA and the patient advocacy group Dyskeratosis Congenita Outreach (now known as Team Telomere), focused on vascular complications of telomere biology disorders.²⁰

Methods

This was an international multicenter retrospective review of patients with telomere biology disorders cared for at CCCTAA member centers who experienced any form of GI bleeding (eg, hematemesis, hematochezia, or melena). A call for cases was sent to 39 members representing 25 institutions, including 12 non-US sites. Twenty-five of the 39 members queried were pediatric hematologists or bone marrow transplantation physicians, and 4 were from other pediatric subspecialties. Eight cared for adult patients, and 2 were clinical geneticists. Baylor College of Medicine was the data coordinating center and facilitated data use agreements with respondents. Institutional review board approval was obtained from Baylor College of Medicine, and institutional review board approval or a waiver of requirement for approval was also obtained from other participating centers. Data abstracted from the medical record included demographics, clinical and genetic diagnoses, laboratory testing, imaging, and medical and procedural management. Data are presented as frequency or median with range. The denominators vary based on the number of responses for a specific data element.

Results

Demographics and Clinical Characteristics

Sixteen patients were identified at 11 centers as having experienced 1 or more episodes of GI hemorrhage. Ten of these patients came from 7 centers that treated a total of 74 patients with telomere biology disorders. Nonetheless, the prevalence of this complication would be best determined by a prospective study via an international telomere biology disorder registry. Summaries of the clinical course for each patient are provided in **Table I** (available at www.jpeds.com). Patients experienced their initial telomere biology disorder clinical feature at a median of 3.5 years of age but did not receive a formal telomere biology disorder diagnosis until a median of 9.5 years of age (**Table II**). Elements of the classic mucocutaneous triad were not uniformly present, with as few as 5 of 16 patients (31%) demonstrating oral leukoplakia and 9 or 10 of 16 (~60%) exhibiting skin pigmentation or nail dysplasia. Although 5 patients had a diagnosis of Coats plus, which is known to predispose to GI hemorrhage,^{5,6} 8 were categorized with dyskeratosis congenita, in which GI hemorrhage is less well characterized. Heterozygous *TINF2* sequence variants were present in one-half of the cohort (8 of 16). Biallelic *CTC1* and *STN1* sequence variants were present in 2 patients each.

Thirteen patients (81%) had a history of bone marrow failure (**Table II**); however, none received androgen therapy, which may be used to treat telomere biology disorder-associated marrow failure^{21,22} before their first GI bleed. Ten patients (62%) underwent hematopoietic cell transplantation (HCT) at a median of 5.5 years (range, 0-13 years) before the initial GI bleed. Reduced-intensity conditioning was used in all but 1 case, in which the patient received high-dose cyclophosphamide. Regimens were highly variable but commonly included cyclophosphamide, alemtuzumab, and fludarabine.

Clinical Features and Treatment of the Initial GI Hemorrhage

The initial GI bleed occurred at a median of age 12.5 years (range, 0.8-36 years). When analyzed separately, the patients without Coats plus ($n = 11$) experienced their first GI bleed at an earlier median age (14 years; range, 0.83-36 years) compared with those with Coats plus ($n = 5$) (median age, 25 years; range, 14-31 years). The 2 groups were not distinguishable by any other features relating to their GI bleed (**Table I**), and thus they were evaluated together for the remaining analyses.

Bleeds most commonly presented as melena or hematochezia (**Table III**). All patients presented with anemia characterized by a hemoglobin concentration of <10 mg/dL, representing a median decline in baseline hemoglobin of 3.7 mg/dL. Although nearly all patients had thrombocytopenia, and 3 had a mildly prolonged international normalized ratio (maximum, 1.43 seconds),

none presented with features concerning for a bleeding diathesis.

GI endoscopy was performed during most of the initial bleeds (12 of 16; 75%; **Table III**). Six capsule endoscopy procedures and 3 push enteroscopies were performed to visualize the small bowel beyond the reach of regular endoscopes, suggesting that these patients might have had obscure GI bleeding not explainable after standard endoscopy. **Figure 1** shows representative endoscopic findings in the esophagus and stomach. Esophageal findings ranged from normal to mild mucosal irregularities, such as linear furrowing. Four patients had esophageal varices, none actively bleeding at the time of endoscopy. A single varix in 1 patient underwent band ligation during endoscopy. The stomach was affected in 6 patients, 3 of whom had Coats plus, typically with patchy,

Table II. Demographic and clinical characteristics of the study cohort (N = 16)

| Characteristics | Value |
|--|--------------|
| Female sex, n (%) | 8 (50) |
| Age at first major telomere biology disorder complication, y, median (range) | 3.5 (0.8-16) |
| Age at telomere biology disorder diagnosis, y, median (range) | 9.5 (1-36) |
| Age at last follow up or death, y, median (range) | 16 (2-37) |
| Deceased, n (%) | 12 (75) |
| History of other telomere biology disorder clinical manifestations, n (%) | |
| Mucocutaneous triad | 5 (31) |
| Oral leukoplakia | 10 (62) |
| Skin pigmentation abnormalities | 9 (56) |
| Nail dysplasia | 13 (81) |
| Bone marrow failure | 7 (54) |
| Retinopathy | 3 (20) |
| Pulmonary AVM | |
| Clinical telomere biology disorder diagnosis, n (%) | |
| Dyskeratosis congenita | 8 (50) |
| Coats plus syndrome | 5 (31) |
| Revesz syndrome | 2 (12) |
| Hoyeraal–Hreidarsson syndrome | 1 (6) |
| Telomere biology disorder gene mutation, n (%) | |
| <i>TINF2</i> (monoallelic)* | 8 (50) |
| <i>CTC1</i> (biallelic) | 2 (12) |
| <i>STN1</i> (biallelic) | 2 (12) |
| <i>TERC</i> (monoallelic)† | 1 (6) |
| <i>RTEL1</i> (biallelic) | 1 (6) |
| Not tested | 2 (12) |
| History of PRBC transfusion before first GI bleed (n = 15), n (%) | 14 (93) |
| History of platelet transfusion before first GI bleed (n = 15), n (%) | 12 (80) |
| History of androgen treatment before first GI bleed, n (%) | 0 (0) |
| History of HCT, n (%) | 10 (62) |
| Age at HCT, y, median (range) | 3 (1-36) |
| Source of donor bone marrow (n = 10), n (%) | |
| Matched related | 5 (50) |
| Matched unrelated | 5 (50) |
| Conditioning regimens, n (%) | |
| Cyclophosphamide | 7 (70) |
| Alemtuzumab | 6 (60) |
| Fludarabine | 5 (50) |
| Antilymphocyte or antithymocyte globulin | 4 (40) |

AVM, arteriovenous malformation.

*One patient with a novel synonymous variant.

†Variant of unknown significance.

Table III. Clinical features of the initial GI bleed (N = 16)

| Features | Values |
|--|---------------|
| Age at first GI bleed, y, median (range) | 12.5 (0.8-36) |
| Presenting signs/symptoms, n (%) | |
| Melena | 8 (50) |
| Hematochezia | 7 (44) |
| Hematemesis | 4 (25) |
| Hemoglobin at presentation, mg/dL, median (range) | 6.7 (4.8-9.9) |
| Hemoglobin decline at presentation from previous baseline, mg/dL, median (range) | 3.7 (0.2-11) |
| Diagnostic studies | |
| Upper and/or lower endoscopy performed, n (%) | 12 (75) |
| Time to endoscopy, d, median (range) | 2 (1-24) |
| Additional evaluations, n (%) | |
| Capsule endoscopy | 6 (37) |
| Push enteroscopy | 3 (19) |
| Endoscopic findings (N = 12), n (%) | |
| Angiodysplasia | 8 (67) |
| Esophageal varices | 4 (33) |
| Portal hypertensive gastropathy | 1 (8) |
| Supportive interventions | |
| Intensive care unit admission (N = 16), n (%) | 4 (25) |
| Hospital length of stay, d, median (range) | 7 (2-45) |
| PRBC transfusion (N = 15), n (%) | 14 (93) |
| Platelet transfusion (N = 15), n (%) | 9 (60) |
| Therapeutic interventions, medical, n (%) | |
| Proton pump inhibitors | 14 (88) |
| Octreotide | 7 (44) |
| Sucralfate | 6 (37) |
| Beta blockers | 3 (19) |
| Androgen | 3 (19) |
| Estrogen | 2 (12) |
| Bowel rest | 2 (14) |
| Stiripiridol | 1 (6) |
| Therapeutic interventions, endoscopic and surgical, n (%) | |
| Radiofrequency ablation | 2 (12) |
| Argon plasma coagulation | 2 (12) |
| Transjugular intrahepatic portosystemic shunt | 1 (6) |
| Bipolar electrocautery | 1 (6) |
| Outcomes, n (%) | |
| Additional GI bleeds, n (%) | 15 (94) |
| Additional hospitalizations related to GI bleeding, median (range) | 5 (0-16) |
| Additional endoscopic procedures, median (range) | 2 (1-11) |
| Surgery related to GI bleeding, n (%) | 2 (12) |

often antral-predominant erythema (**Figure 1**, D-F). Endoscopists described the findings with such terms as “telangiectasia,” “gastritis,” “gastric antral variceal ectasia” (GAVE), “ectatic,” “vascular dysplasia,” and “fragile vessels.” **Figure 2** shows representative endoscopic findings in the small bowel. Small bowel findings mimicked gastric findings with vascular-appearing erythematous lesions (**Figure 2**, A-F). Lesions in the colon, which was less commonly affected than the stomach and small bowel, were described as having the appearance of “vascular ectasia” and “friability.”

Most patients were managed supportively outside the intensive care unit, with packed red blood cells (PRBCs) and/or platelet transfusions during a median hospital stay of 7 days (maximum, 45 days; **Table III**). Proton pump inhibitors were the most commonly used medication (in 14




Figure 1. Representative endoscopic photographs from the esophagus and stomach. Findings in the esophagus were variable, ranging from **A**, normal, to **B**, linear furrowing, to **C**, presence of nonbleeding varices. **D-F**, The stomach was commonly affected, typically with a patchy, antral predominant erythema. Frequently, the lesions appear as discrete “pinpoints” occurring closely together in clusters.




Figure 2. Representative endoscopic photographs from the small intestine. **A-C**, Endoscopic findings in the proximal small bowel were common and similar in appearance to the gastric lesions. **D-F**, Findings in more distal aspects of the small bowel, imaged with capsule endoscopy in 6 patients. Shown are areas of **D**, patchy erythema, **E**, ectatic superficial vessels, and **F**, and confluent areas of erythema.

in 16 patients; 88%), followed by octreotide, sucralfate, beta-blockers, and androgens. Although the investigators felt that no single medical therapy resulted in resolution of bleeding, 4 patients were considered to have had complete resolution of bleeding while being treated with multiple medical and supportive interventions. In the remaining patients, the initial bleeding episode eventually ceased, but this was not considered to be due to any particular intervention(s). There were no patient deaths directly attributed to the initial GI bleed.

Endoscopic and surgical therapies were infrequently used for initial GI bleeds (Table III). Argon plasma coagulation (APC) was used twice on gastric antral variceal ectasia-type lesions, and 1 patient showed a partial response. Radiofrequency ablation (RFA) of vascular gastric lesions was performed twice in patients who previously underwent APC, with 1 patient exhibiting a partial response. A transjugular intrahepatic portosystemic shunt was implanted in 1 patient in whom portal hypertension was felt to have a possible role; however, it appeared to have only a minimal impact on bleeding.

Features of Liver Disease

Most patients did not have biochemical evidence of clinically significant concurrent liver disease in the 6 months before or at the time of the initial GI bleed (Table IV; available at www.jpeds.com). At the time of the initial bleed, serum aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transferase levels were within the normal range in 93%, 73%, and 62%, respectively, of patients for whom data were available. Excretory liver function was maintained, with a normal total bilirubin level in 75% (9 of 12). Although serum albumin level was normal in only 15% (2 of 13), the international normalized ratio was normal in 62% (5 of 8); thus, the extent to which liver synthetic function was impaired is not clear. Features of portal hypertension were present in fewer than one-half of patients at the time of the initial GI bleed, including esophageal varices in 33% (4 of 12), splenomegaly in 38% (6 of 16), and ascites in 31% (5 of 16). Five patients underwent liver biopsy analysis, of whom 4 showed varying degrees of fibrosis. At the most recent follow-up, fewer patients had normal aspartate aminotransferase (43%), alanine aminotransferase (46%), total bilirubin (31%), and albumin (38%) than before the initial GI bleed, and more patients had splenomegaly (50%) than before the initial GI bleed, suggesting the possibility of evolving liver disease (Table IV). Four patients (25%) were formally evaluated for liver transplantation; however, none had undergone transplantation at the time of this report.

Recurrence of GI Hemorrhage

Recurrence of GI hemorrhage occurred in 15 of 16 patients (94%), resulting in a median of 5 additional hospitalizations, with 1 patient hospitalized for GI bleeding 16 additional times (Table III). One or 2 additional endoscopic

procedures were performed in one-half the patients, with the other one-half undergoing up to 11 procedures.

Thalidomide was used in 2 patients, without a clear response. Bevacizumab was trialed in 2 patients. One did not respond; however, the other appeared to have benefited. Although the response became apparent after the initial data collection and analysis, given its remarkable nature, further information was collected and provided here. The patient had multiple GI telangiectasia and recurrent GI bleeding, requiring up to 10 PRBC transfusions per month (Figure 3; available at www.jpeds.com). Treatment with octreotide (short- and long-acting), proton pump inhibitors, and thalidomide did not lead to any sustained impact on bleeding or reduce the need for transfusions. At 9 months after the first episode of bleeding, and following the administration of 50 separate PRBC transfusions, intravenous bevacizumab, 5 mg/kg/dose once every 4 weeks, was started. There was a profound and sustained response, with no transfusions required for the subsequent 7 months. Treatment was withheld to allow for the surgical insertion of a feeding tube, with some increase in bleeding following the procedure, followed by a further reduction in bleeding after restarting treatment with bevacizumab.

Long-Term Outcomes

Twelve patients (75%) were deceased at the time of data collection, with a median age at death of 16.5 years (range, 2-37 years) (Table II). The median time between the index GI bleed and death was 2 years (range, <1-7 years). Whether a subsequent episode of GI bleeding was the proximate cause of death was not captured; however, the patients had a variety of comorbidities that may have been contributory, such as pulmonary fibrosis, hepatopulmonary syndrome, stage 4 chronic kidney disease, and small bowel obstruction.

Discussion

This series reveals recurrent GI hemorrhage in patients with an underlying telomere biology disorder as a major cause of morbidity for which empiric management strategies have proven ineffective. Although the pathophysiology underlying the GI bleeding remains to be elucidated, certain conclusions can be drawn. First, GI hemorrhage is not exclusive to patients with Coats plus, but also may be observed in patients with dyskeratosis congenita, Hoyeraal-Hreidarsson syndrome, and Revesz syndrome. However, it may be more prevalent in patients with *TINF2*, *CTC1*, or *STN1* mutations, as these genes accounted for 12 of 14 patients in our series who had genetic testing. Given the association of *CTC1* and *STN1* mutation with Coats plus, which has been reported to be associated with GI hemorrhage,^{5,6} disease due to these 2 mutations is expected, even in the absence of overt Coats plus. However, the enrichment of *TINF2* cases in particular, with an absence of *DKC1* and *TERT* cases, is notable. *TINF2*-associated disease is known to be more

severe, with early presentation and association with both Hoyeraal–Hreidarsson syndrome and Revesz syndrome phenotypes.^{13,14} There may be a specific vascular pathology that derives from mutations in *TINF2*, like *CTC1* and *STN1*, which also may be reflected by the nearly exclusive occurrence of Coats disease in telomere biology disorders owing to mutation in these genes.^{5,6,10,13,14}

In addition, we found the median age of the first GI hemorrhage for the entire cohort was 12.5 years. This could reflect the natural history of cases that are severe in many respects, such as early age of telomere biology disorder presentation, need for HCT, multisystem involvement, and premature death. Alternatively, but less likely, it could represent the population from which the cases were drawn, given that the majority of CCCTAA member institutions at the time of the call for cases were pediatric centers. Interestingly, the median age at the first GI bleed was higher for the patients with Coats plus than for those without Coats plus alone, although a patient as young as 3 years with Coats plus and GI hemorrhage has been reported.³

Most patients experienced their first GI bleeding event after HCT. Therefore, patients and families should be counseled about this potential disease manifestation even after successful HCT. There were also patients who had not undergone HCT at the time of their GI hemorrhage. Thus, hemorrhage appears to be attributable not to HCT, but rather to the natural history of disease in some patients.

The presence of telangiectatic superficial vessels in the stomach and small intestine in many patients suggests that vasculopathy may underlie GI bleeding. Although features of portal hypertension, including esophageal varices, were present in 4 patients at the time of the initial bleed, these did not appear to be the proximate cause of the GI bleeding, and GI bleeding was not ameliorated in 1 patient who underwent transjugular intrahepatic portosystemic shunt for treatment of portal hypertension.

The management of GI hemorrhage proved challenging across the institutions caring for these patients. The wide variety of medical interventions used during these events highlights the lack of consensus regarding the pathophysiology of the GI bleeding in patients with telomere biology disorders. Although some measures were general in nature, other therapies were aimed at reducing portal hypertension or ulcer-related bleeding. Hormones, both androgens and estrogen, were used, as was sirolimus, for its purported antiangiogenic properties. No single medical therapy emerged in our series as highly efficacious, with the exception of potential response to bevacizumab in 1 of 2 patients who received it. RFA was used in 2 patients who had previously been treated with APC and was felt to be more helpful than the initial APC. The diffuse nature of the GI lesions in patients with GI bleeding may limit the utility of site-directed interventions like these, however.

GI hemorrhage in patients with a telomere biology disorder is associated with significant morbidity. A unifying

mechanism of telomere biology disorder–related GI bleeding remains elusive; however, vascular ectasias appear to be common. Treatment modalities that lead to rapid cessation of bleeding and prevention of recurrence are needed. The development of a prospective international registry focused on GI vascular manifestations of telomere biology disorders would be an important first step in improving patient outcomes. Based on the apparent response in 1 patient in this series, bevacizumab warrants further investigation as a potential treatment for telomere biology disorder–associated GI bleeding. ■

We are grateful for Team Telomere's support of the CCCTAA's research effort. We thank Cynthia Tsai, Senior Research Coordinator, Texas Children's Hospital, for research operations support.

Submitted for publication May 21, 2020; last revision received Aug 17, 2020; accepted Sep 16, 2020.

Reprint requests: Ryan W. Himes, MD, Ochsner Health, 1315 Jefferson Hwy, New Orleans, LA 70121. E-mail: ryan.himes@ochsner.org

Data Statement

Data sharing statement available at www.jpeds.com.

References

1. Savage SA. Beginning at the ends: telomeres and human disease. *F1000Res* 2018;7:F1000. Faculty Rev-524.
2. Dodson L, Bertuch AA. Dyskeratosis congenita and the telomere biology disorders. In: Kupfer GM, Reaman GH, Smith FO, eds. *Bone marrow failure*. Cham, Switzerland: Springer International; 2018. p. 111-27.
3. Briggs TA, Abdel-Salam GM, Balicki M, Baxter P, Bertini E, Bishop N, et al. Cerebroretinal microangiopathy with calcifications and cysts (CRMCC). *Am J Med Genet A* 2008;146A:182-90.
4. Briggs TA, Hubbard M, Hawkins C, Cole T, Livingston JH, Crow YJ, et al. Treatment of gastrointestinal bleeding in a probable case of cerebroretinal microangiopathy with calcifications and cysts. *Mol Syndromol* 2011;1:159-62.
5. Simon AJ, Lev A, Zhang Y, Weiss B, Rylova A, Eyal E, et al. Mutations in *STN1* cause Coats plus syndrome and are associated with genomic and telomere defects. *J Exp Med* 2016;213:1429-40.
6. Polvi A, Linnankivi T, Kivelä T, Herva R, Keating JP, Mäkitie O, et al. Mutations in *CTC1*, encoding the CTS telomere maintenance complex component 1, cause cerebroretinal microangiopathy with calcifications and cysts. *Am J Hum Genet* 2012;90:540-9.
7. Alter BP, Rosenberg PS, Giri N, Baerlocher GM, Lansdorf PM, Savage SA. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. *Haematologica* 2012;97:353-9.
8. Alter BP, Baerlocher GM, Savage SA, Chanock SJ, Weksler BB, Willner JP, et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. *Blood* 2007;110:1439-47.
9. Savage SA. *Dyskeratosis congenita*. Seattle (WA): University of Washington; 2009 [updated November 21, 2019].
10. Anderson BH, Kasher PR, Mayer J, Szykiewicz M, Jenkinson EM, Bhaskar SS, et al. Mutations in *CTC1*, encoding conserved telomere maintenance component 1, cause Coats plus. *Nat Genet* 2012;44:338-42.

11. Takai H, Jenkinson E, Kabir S, Babul-Hirji R, Najm-Tehrani N, Chitayat DA, et al. A POT1 mutation implicates defective telomere end fill-in and telomere truncations in Coats plus. *Genes Dev* 2016;30:812-26.
12. Sharma A, Myers K, Ye Z, D'Orazio J. Dyskeratosis congenita caused by a novel TERT point mutation in siblings with pancytopenia and exudative retinopathy. *Pediatr Blood Cancer* 2014;61:2302-4.
13. Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM, Alter BP. TIN2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. *Am J Hum Genet* 2008;82:501-9.
14. Walne AJ, Vulliamy T, Beswick R, Kirwan M, Dokal I. TIN2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. *Blood* 2008;112:3594-600.
15. Drachtman RA, Alter BP. Dyskeratosis congenita. *Dermatol Clin* 1995;13:33-9.
16. Kirwan M, Dokal I. Dyskeratosis congenita: a genetic disorder of many faces. *Clin Genet* 2008;73:103-12.
17. Chatura KR, Nadar S, Pulimood S, Mathai D, Mathan MM. Case report: gastric carcinoma as a complication of dyskeratosis congenita in an adolescent boy. *Dig Dis Sci* 1996;41:2340-2.
18. Jonassaint NL, Guo N, Califano JA, Montgomery EA, Armanios M. The gastrointestinal manifestations of telomere-mediated disease. *Aging Cell* 2013;12:319-23.
19. Gorgy AI, Jonassaint NL, Stanley SE, Koteish A, DeZern AE, Walter JE, et al. Hepatopulmonary syndrome is a frequent cause of dyspnea in the short telomere disorders. *Chest* 2015;148:1019-26.
20. Higgs C, Crow YJ, Adams DM, Chang E, Hayes D Jr, Herbig U, et al. Understanding the evolving phenotype of vascular complications in telomere biology disorders. *Angiogenesis* 2019;22:95-102.
21. Khincha PP, Wentzensen IM, Giri N, Alter BP, Savage SA. Response to androgen therapy in patients with dyskeratosis congenita. *Br J Haematol* 2014;165:349-57.
22. Islam A, Rafiq S, Kirwan M, Walne A, Cavenagh J, Vulliamy T, et al. Haematological recovery in dyskeratosis congenita patients treated with danazol. *Br J Haematol* 2013;162:854-6.

50 Years Ago in *THE JOURNAL OF PEDIATRICS*

Understanding the Molecular Basis of 11p13 Deletion

Haicken BN, Miller DR. Simultaneous occurrence of congenital aniridia, hamartoma and Wilms' tumor. *J Pediatr* 1971;78:497-502

Haicken and Miller reported a 17-month-old female infant with aniridia, Wilms' tumor, microcephaly, spina bifida with meningocele, and lipoma. This child had features associated with Wilms' tumor–aniridia syndrome and represented the first occurrence of sacral lipoma and meningocele with this condition. This case represented the 25th case reported in which aniridia occurred in association with Wilms' tumor and the third reported case in which a hamartoma occurred in association with Wilms' tumor–aniridia, suggesting a link between this disorder and disorders of growth control. It had been proposed by Miller et al that a mutagenic agent could be responsible for both aniridia and Wilms' tumor.¹

Subsequent studies demonstrated a de novo 11p13 deletion resulting in a contiguous gene deletion syndrome in patients with Wilms' tumor–aniridia genitourinary anomalies and mental retardation syndrome (WAGR). Although the size of the 11p13 deletion may vary among different patients, *PAX6* and *WT1* are critical genes in this genomic region.² *PAX6* encodes a transcriptional factor that is responsible for lens placode development. *WT1* encodes a zinc finger binding protein acting as a transcriptional activator or repressor and is responsible for normal genitourinary development.

The phenotypic spectrum of WAGR syndrome includes 50% risk for Wilms' tumor in addition to elevated risk for movement disorders, scoliosis, obesity, obstructive sleep apnea, polydactyly, diaphragmatic hernia, behavior, auditory processing deficits, and psychiatric problems. End-stage renal disease is associated with WAGR and includes focal segmental glomerulosclerosis. Early diagnosis of WAGR is extremely important, as WAGR-associated Wilms' tumor is associated with a more favorable histology prognosis as compared with isolated Wilms' tumor.

Philip F. Giampietro, MD, PhD

Division of Medical Genetics
Rutgers-Robert Wood Johnson Medical School
New Brunswick, New Jersey

References

1. Miller RW, Fraumeni JF, Manning MD. Association of Wilms' tumor with aniridia, hemihypertrophy, and other congenital malformations. *N Engl J Med* 1964;270:922-7.
2. Riccardi VM, Sunansky E, Smith AC, Francke U. Chromosomal imbalance in the aniridia-Wilms tumor association: 11p interstitial deletion. *Pediatrics* 1978;61:604-10.




Figure 3. Red blood cell transfusion requirement for a patient treated with bevacizumab. Dark arrows indicate the start of bevacizumab treatment. The dashed arrow indicates the period during which bevacizumab was withheld for performance of a surgical gastrostomy.

Table I. Key clinical features of individual patients in the cohort

| Subject number | Telomere biology disorder category | Gene mutated | Age at diagnosis of first major complication of telomere biology disorder, y | Age at HSCT, y, if applicable | Age at first GI bleed, y | Current age or age of death, y | Duration of first hospitalization, d | Number of additional GI bleeds requiring hospitalization | Number of endoscopies | Comorbidities at time of study entry or death |
|----------------|------------------------------------|--------------|--|-------------------------------|--------------------------|--------------------------------|--------------------------------------|--|-----------------------|---|
| 1 | Coats plus | <i>CTC1</i> | Childhood | 24 | 25 | 26 at death | 7 | 5 | 11 | Liver disease with ascites and hyperammonemia, portal vein thrombosis, small bowel obstruction with perforation, surgical asplenia, avascular necrosis of the femoral heads |
| 2 | Coats plus | <i>CTC1</i> | 4 | N/A | 28 | 28 | 4 | 2 | 1 | Moderate pancytopenia, pulmonary fibrosis with clubbing, liver fibrosis/cirrhosis, and dysplasia with portal hypertension and ascites, recurrent spontaneous fractures, h/o retinal hemorrhages |
| 3 | Coats plus | <i>STN1</i> | 13 | N/A | 14 | 16 at death | NR | 5 | 6 | No entry |
| 4 | Coats plus | <i>STN1</i> | 16 | N/A | 19 | 23 at death | 45 | Many | 5 | No entry |
| 5 | Coats plus | unknown | 6 | 31 | 31 | 31 at death | 2 | 0 | 1 | Pancytopenia, liver disease with ascites, renal insufficiency, viral and fungal infections |
| 6 | Dyskeratosis congenita | <i>TERC</i> | NR | N/A | 36 | 37 at death | 25 | 2 | 2 | Moderate restrictive lung defect, diffuse alveolar hemorrhage, transaminitis, traumatic right subdural hemorrhage, neutropenic sepsis, <i>Burkholderia pneumonia</i> |
| 7 | Dyskeratosis congenita | <i>TINF2</i> | 0.83 | 1 | 7 | 9 at death | 17 | NR | NR | Buphthalmos right, persistent hyperplastic primary vitreous body left, distinct psychomotor developmental delay, perforated stenosis in the area of the upper esophageal sphincter, hyperthyroidism, hypoxia |
| 8 | Dyskeratosis congenita | <i>TINF2</i> | 1 | 3 | 11 | 12 at death | 6 | 6 | 3 | Nasolacrimal duct obstruction, pulmonary fibrosis, dysphagia due to esophageal web, Budd-Chiari syndrome, portal hypertension, leg edema, adjustment disorder with mixed anxiety and depressed mood, malnutrition |
| 9 | Dyskeratosis congenita | <i>TINF2</i> | 2 | 3 | 7 | 9 at death | NR | 14 | 1 | Aplastic anemia |
| 10 | Dyskeratosis congenita | <i>TINF2</i> | 4 | 4 | 9 | 12 at death | 14 | 15 | 5 | Nasolacrimal duct stenosis, pulmonary nodule, pulmonary fibrosis, aortic root dilatation, portal hypertension, genu valgum |
| 11 | Dyskeratosis congenita | <i>TINF2</i> | 5 | N/A | 5 | 7 at death | 30 | 16 | 2 | Pulmonary restrictive dysfunction, spontaneous tibia and fibula fractures |

(continued)

Table I. Continued

| Subject number | Telomere biology disorder category | Gene mutated | Age at diagnosis of first major complication of telomere biology disorder, y | Age at HSCT, y, if applicable | Age at first GI bleed, y | Current age or age of death, y | Duration of first hospitalization, d | Number of additional GI bleeds requiring hospitalization | Number of endoscopies | Comorbidities at time of study entry or death |
|----------------|------------------------------------|--------------|--|-------------------------------|--------------------------|--------------------------------|--------------------------------------|--|-----------------------|--|
| 12 | Dyskeratosis congenita | <i>TINF2</i> | 5 | 5 | 18 | 25 at death | 7 | 4 | 4 | Pulmonary fibrosis, hypoxemia, portal venous hypertension, hyperammonemia, generalized abdominal pain, small bowel obstruction s/p adhesiolysis, chronic kidney disease, stage 4, erythropoietin deficiency anemia, genu valgum, adjustment disorder with mixed anxiety and depressed mood |
| 13 | Dyskeratosis congenita | unknown | 2 | 3 | 15 | 17 at death | 8 | 2 | Multiple | Pulmonary fibrosis, hepatic fibrosis, history of multiple fractures with minimal trauma |
| 14 | Hoyeraal–Hreidarsson syndrome | <i>RTEL1</i> | 1 | N/A | 0.83 | 2 | NR | NR | 1 | Colitis |
| 15 | Revesz syndrome | <i>TINF2</i> | 2 | 2 | 4 | 5 | 2 | 5 | 2 | Mild hemophilia A, developmental delay, expressive language delay |
| 16 | Revesz syndrome | <i>TINF2</i> | 3 | 3 | 10 | 10 | 4 | 6 | 2 | Persistent thrombocytopenia, iron deficiency anemia, lacrimal duct occlusion, constipation, vesicoureteral reflux, urethral stenosis, phimosis, multiple fractures |

N/A, not applicable; NR, not recorded.

Table IV. Liver-related findings

| Parameters | 6 mo before first GI bleed (N = 16) | At time of first GI bleed (N = 16)* | At most recent follow-up (N = 14) |
|---|--|--|--------------------------------------|
| Clinical features, n (%) | | | |
| Splenomegaly | 6 (38) | 6 (38) | 7 (50) |
| Ascites | 6 (38) | 5 (31) | 4 (29) |
| Varices | 2 (12) | 4 (33) | NA |
| Pruritus | 1 (6) | NA | NA |
| Jaundice | 1 (6) | NA | NA |
| Hepatic encephalopathy | 0 (0) | NA | NA |
| Laboratory tests, median (range); normal results, n (%) | | | |
| AST, U/L | 14 (29-105); 9 (64) | 14 (17-91); 13 (93) | 14 (19-507); 6 (43) |
| ALT, U/L | 14 (6-62); 8 (57) | 15 (8-161); 11 (73) | 13 (9-136); 6 (46) |
| GGT, U/L | 8 (13-199); 3 (37) | 18 (12-172); 5 (62) | 8 (7-281); 4 (50) |
| Total bilirubin, mg/dL | 0.64 (0.13-4.3); 9 (75) | 0.82 (0.1-3); 9 (75) | 1.42 (0.2-19.7); 5 (31) |
| Albumin, g/dL | 3.5 (2.3-4.2); 8 (61) | 2.7 (1.7-3.2); 2 (15) | 2.7 (<1.5-6); 5 (38) |
| Platelets, $\times 10^9/L$ | 74 (6-269); 2 (16) | 72 (2-374); 1 (7) | NA |
| INR | NA | 1.2 (0.9-1.43); 5 (62) | 1.1 (0.9-2.2); 7 (64) |
| Liver transplantation (N = 16), n (%) | | | |
| Formally evaluated | | 4 (25) | |
| Underwent liver transplantation | | 0 (0) | |

AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; INR, international normalized ratio; NA, not asked.

*Except for varices, for which only 12 patients underwent endoscopy.

| Laboratory test | Normal cutoff |
|----------------------------|---------------|
| AST, U/L | <60 |
| ALT, U/L | <35 |
| GGT, U/L | <50 |
| Total bilirubin, mg/dL | <1 |
| Albumin, g/dL | >3 |
| Platelets, $\times 10^9/L$ | >150 |
| INR | <1.2 |